# Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

> **NCT07374250** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 154 (estimated)

## Conditions studied

- Gastric Cancer
- RCT

## Interventions

- **DRUG:** Ivonescimab (20mg/kg Q3W)
- **DRUG:** Oxaliplatin
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT07374250
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07374250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07374250, "Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07374250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*